Replimune Group, Inc.
Replimune Group, Inc.（REPL）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · REPL · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
12
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Replimune Group, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
REPL 季度内部人买卖趋势
REPL 内幕交易卖出 · REPL 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · REPL CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
REPL 高管卖出股份 · REPL 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 12,000 | $111K | Form 4 |
| May 18, 2026 | Xynos Konstantinos Chief Medical Officer | Sale | 14,023 | $71K | Form 4 |
| May 18, 2026 | Schwendenman Andrew CAO | Sale | 7,894 | $40K | Form 4 |
| May 18, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 8,626 | $44K | Form 4 |
| May 18, 2026 | Astley-Sparke Philip Director | Sale | 17,657 | $90K | Form 4 |
| May 18, 2026 | Patel Sushil CEO · Director | Sale | 37,324 | $190K | Form 4 |
| May 18, 2026 | Hill Emily Luisa CFO | Sale | 7,812 | $40K | Form 4 |
| Apr 1, 2026 | Sarchi Christopher Chief Commercial Officer | Award | 50,000 | — | Form 4 |
| Apr 1, 2026 | Astley-Sparke Philip Director | Award | 50,000 | — | Form 4 |
| Apr 1, 2026 | Xynos Konstantinos Chief Medical Officer | Award | 50,000 | — | Form 4 |
| Apr 1, 2026 | Schwendenman Andrew CAO | Award | 36,667 | — | Form 4 |
| Apr 1, 2026 | Patel Sushil CEO · Director | Award | 251,240 | — | Form 4 |
| Apr 1, 2026 | Hill Emily Luisa CFO | Award | 50,000 | — | Form 4 |
| Apr 2, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 6,500 | $52K | Form 4 |
| Feb 18, 2026 | Astley-Sparke Philip Director | Gift | 25,000 | — | Form 4 |
| Dec 19, 2025 | Patel Sushil CEO · Director | Award | 200,000 | — | Form 4 |
| Dec 19, 2025 | Xynos Konstantinos Chief Medical Officer | Award | 60,000 | — | Form 4 |
| Dec 19, 2025 | Hill Emily Luisa CFO | Award | 60,000 | — | Form 4 |
| Dec 19, 2025 | Sarchi Christopher Chief Commercial Officer | Award | 35,000 | — | Form 4 |
| Dec 19, 2025 | Schwendenman Andrew CAO | Award | 10,000 | — | Form 4 |
| Dec 9, 2025 | Dhingra Kapil Director | Option | 3,169 | $6K | Form 4 |
| Dec 9, 2025 | Dhingra Kapil Director | Sale | 3,169 | $33K | Form 4 |
| Dec 2, 2025 | Patel Sushil CEO · Director | Sale | 10,000 | $111K | Form 4 |
| Nov 17, 2025 | Sarchi Christopher Chief Commercial Officer | Sale | 5,208 | $47K | Form 4 |
| Nov 17, 2025 | Xynos Konstantinos Chief Medical Officer | Sale | 7,248 | $66K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 REPL 内幕交易
REPL 内幕交易
Replimune Group, Inc.（REPL）内幕交易数据来源于公司内部人（包括Sarchi Christopher (Chief Commercial Officer), Xynos Konstantinos (Chief Medical Officer), Patel Sushil (CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。REPL内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Replimune Group, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
REPL 内幕交易 · 5个问题Replimune Group, Inc.（REPL）的内部人包括高管和董事，如Sarchi Christopher (Chief Commercial Officer), Xynos Konstantinos (Chief Medical Officer), Patel Sushil (CEO · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026